Recombinant human PTH 1-34 (Forteo): an anabolic drug for osteoporosis.
- 1 July 2003
- journal article
- review article
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 70 (7) , 585-586
- https://doi.org/10.3949/ccjm.70.7.585
Abstract
Forteo (teriparatide of rDNA origin), a genetically engineered fragment of parathyroid hormone, is the first of a new class of drugs to treat osteoporosis. The drug's anabolic action increases bone turnover, stimulating osteoblasts to a greater extent than osteoclasts, and reducing both vertebral and nonvertebral fractures. However, a number of issues about its use remain unanswered.Keywords
This publication has 0 references indexed in Scilit: